PKU Gene Therapy

About American Gene Technologies

American Gene Technologies is a private, clinical-stage biotech pioneering gene and cell therapies with a core lentiviral vector platform. Its most advanced program, AGT103-T for an HIV cure, has completed a Phase 1 trial and received FDA Fast Track designation, demonstrating early safety and signals of reservoir reduction. The company is also developing an immuno-oncology approach (ImmunoTox) for solid tumors and a gene therapy for PKU, which holds Orphan Drug status. AGT operates as a platform company aiming to reduce the time and cost of developing new genetic medicines.

Therapeutic Areas